Virolens: Pre-presentation

Virolens: Pre-presentation

Protect and Care has secured the rights to bring the Virolens® testing units to the whole of Europe, EEA and Overseas territories.

From April 26 to 28, Protect and Care holds the first presentation and test demonstration within the EU at the Health & Care fair in Gent, Belgium. With this demonstration we intend to raise awareness of this new and disruptive technology to the medical sector. We intend to convince several renowned hospitals and virologists to support the project.

The highly scalable Virolens® COVID-19 screening device is based on nano-cellular microscope using holographic imaging and artificial intelligence (AI) software technology. It utilizes a non-intrusive saliva swab test to detect the presence of the COVID-19 virus within 20 seconds. The Virolens® system has a 99.8% sensitivity and 96.7% specificity, based on the results of an internal in-vitro validation study, designed by the University of Bristol.

Virolens® can detect COVID in as little as 18 hours after exposure to the virus. At this early stage, the  infected person does not show symptoms and is not contagious, allowing Virolens® do what no other COVID test can’t do:  The chance to get ahead of the virus by isolating the positive person and stopping COVID before it spreads.

In addition to speed and accuracy, Virolens® is mobile and scalable. Unlike PCR and antigen rapid tests that rely on  chemistry to detect the virus, Virolens® is physics-based and does not require chemicals or laboratories. Results are scannable with a  unique QR code and can be shared on an app, in text or printed.

A user simply opens the cartridge lid, swabs their tongue, closes the cartridge and inserts it into the machine. Within seconds the presence or absence of Covid-19 is revealed via a red or green light, depending on the result. (link to video)

Virolens® can detect any enveloped virus it is taught to identify, including Ebola, Hepatitis A and Hepatitis B. In the  near future, Virolens® will test for seven respiratory diseases: Influenza A, Influenza B, MERS, Adenovirus, 229E  (the common cold) and SARS-COV-19.

Protect and Care believes that there will be need for a worldwide network built on the Virolens® system, which needs to be rolled out as soon as possible. This system will allow hundreds of tests per device each day, and play a pivotal role in breaking the chain of transmission of COVID-19 infections. Virolens® has broad applications in sectors such as factories, offices, airports and airlines, events, military, governments, and more. This allows people to go on with their life, knowing that they are in a safe environment.

Protect and Care believes that the markets in these countries will be very large, and will include testing for COVID-19 infections, with an expansion to additional viruses. In the long run these machines will be repurposed as mobile diagnostic laboratories with the potential to rival the present IVD testing industry. Currently, the Virolens® system is only trained to look and recognise COVID-19 but will be extended to other diseases, including the common cold and influenza.

Protect and Care bv
PR Contact information
Ilse Hebbrecht